il 8 (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
96
Structured Review
R&D Systems
il 8
Il 8, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 633 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas/Human+IL-8%2FCXCL8+DuoSet+ELISA/pmc13054578-81-31-33
Average 96 stars, based on 633 article reviews
Il 8, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 633 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/elisas/Human+IL-8%2FCXCL8+DuoSet+ELISA/pmc13054578-81-31-33
Average 96 stars, based on 633 article reviews
il 8 - by Bioz Stars,
2026-09
96/100 stars
Images
1) Product Images from "The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis"
Article Title: The cellular response capacity (CRC) as a novel immunomonitoring approach in sepsis
Journal: Military Medical Research
doi: 10.1016/j.mmr.2026.100010
Figure Legend Snippet: Concentration-dependent change in the humoral inflammatory response following incubation with Escherichia coli ( E. coli ) in the ex vivo whole blood model. a Absolute plasma concentrations of IL-6, IL-8, and MMP9 determined by enzyme-linked immunosorbent assay. b Normalized values and EC 50 curve fit by BuC=0% and 50 000 CFU/ml E. coli= 100%, respectively, for IL-6, IL-8, and MMP9 as indicated by EC 50 (%) on the respective Y-axis. BuC indicates buffer control after 60 min incubation; numbers on the X-axis indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation; LPS indicates lipopolysaccharide (LPS) 100 ng/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, comparing all shown concentrations of E. coli bacteria and 100 ng/ml LPS with BuC. P -values are indicated above the respective data points. ⁎ P <0.05, ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
Techniques Used: Concentration Assay, Incubation, Ex Vivo, Clinical Proteomics, Enzyme-linked Immunosorbent Assay, Control, Bacteria
Figure Legend Snippet: Diagnostic performance for the detection of bacteremia, analyzing the neutrophil phenotype by determining the median fluorescence intensity (MFI) and the cellular response capacity (CRC) in comparison with traditional markers of humoral inflammation (IL-6, IL-8, MMP9). a Comparison of receiver operating characteristic (ROC) at 10,000 CFU/ml Escherichia coli ( E. coli ) with the respective 95% confidence interval (CI) and P -value, and half-maximal effective concentration (EC 50 ) as a function of the E. coli concentration. b Detailed comparison of the EC 50 as a function of the E. coli concentration. c Exemplary comparison of EC 50 curve fit after normalization as indicated by EC 50 (%) on the respective Y-axis to BuC=100% and 50 000 CFU/ml E. coli =0% for the humoral marker IL-6 (the IL-6 values were multiplied by −1 before EC 50 calculation to facilitate comparability with the CRC) and the change in neutrophil phenotype represented by CD11b CRC. BuC indicates buffer control after 60 min incubation; numbers on the X-axis of c indicate E. coli bacteria in concentrations of 2000 to 50 000 CFU/ml after 60 min incubation. Values are shown as median and interquartile range. n =8. Statistical analysis was performed using the Kruskal-Wallis test with Dunn’s post-hoc test, evaluating the EC 50 of IL-8, MMP9, the MFI, and CRC of CD10, CD11b, and CD62L in comparison to the EC 50 of IL-6. P -values are indicated above the respective data points. ⁎ P <0.05. CFU. Colony-forming units; IL. Interleukin; MMP9. Matrix metallopeptidase 9.
Techniques Used: Diagnostic Assay, Fluorescence, Comparison, Concentration Assay, Marker, Control, Incubation, Bacteria
Figure Legend Snippet: Clinical specifications and parameters over all time points of the sepsis cohort. a Suspected infection cause of sepsis. b Distribution of the individual score points of the Sequential Organ Failure Assessment (SOFA) score. c Total SOFA score. d-h Traditional and humoral markers of inflammation: leukocytes and neutrophil-lymphocyte ratio ( d ), C-reactive protein (CRP) and procalcitonin (PCT) ( e ), interleukin-6 (IL-6) and interleukin-8 (IL-8) ( f ), serum amyloid A (SAA) and calprotectin ( g ), matrix metallopeptidase 9 (MMP9) and myeloperoxidase (MPO) ( h ). Values are shown as median and interquartile range. n =14. CNS. Central nervous system; HV. Healthy volunteers.
Techniques Used: Infection
Related Articles
Clinical Proteomics:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available Article Title: Intergenerational impact of paternal low protein diet on offspring bone health in mice. Article Snippet: Total protein levels in the supernatant 153 were determined using the Qubit fluorometer (ThermoFisher Scientific, UK) and the Qubit 154 protein assay kit (Molecular Probes Technologies, UK), in accordance with the manufacturer’s 155 instructions, prior to being stored at -80oC. .. Levels of adiponectin, leptin and Tgfb1 were 156 determined in seminal plasma supernatants using commercial Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available Enzyme-linked Immunosorbent Assay:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available Article Title: A curcumin derivative metalloprotease inhibitor (CMC2.24) mitigates Brachyspira spp.-induced swine dysentery. Article Snippet: Swine dysentery, a mucohemorrhagic diarrheal disease affecting young pigs, is caused by infections in the colon with Brachyspira spp. and threatens the sustainability of the pork industry due to mortality, hindered animal growth, and increased treatment costs.. Given that proteases play critical roles in the progression of colitis, this study evaluated the therapeutic potential of a novel curcumin derivative (CMC 2.24) with matrix metalloproteinase inhibitory properties, CMC2.24, in alleviating the clinical manifestations of swine dysentery.. This study shows that weaned pigs challenged with B. hampsonii and treated with CMC2.24 from days 5 to 9 postchallenge exhibited reduced clinical signs, improved survival rates, and decreased B. hampsonii shedding compared to their untreated counterparts. Flow Cytometry:Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study. Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available Article Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Axatilimab in Healthy Japanese Male Participants: Results from a Phase 1, Randomized, Double-Blind, Dose-Escalation Study Article Snippet: Plasma samples were analyzed for axatilimab using a sandwich enzyme-linked immunosorbent assay (ELISA) with a lower limit of quantitation of 150 ng/mL and an upper limit of quantitation of 10,000 ng/mL. .. Exploratory PD endpoints included change from baseline in CSF-1 and IL-34 levels, assessed by commercially available |
